HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
56:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
recent advances in type 2 diabetes: newer :@0.076190:0.099847:0.792497:0.099847:0.792497:0.063183:0.076190:0.063183:0.019487:0.021503:0.021503:0.021503:0.020159:0.010079:0.009407:0.022175:0.022175:0.018815:0.022175:0.020159:0.021503:0.021503:0.014783:0.009407:0.008063:0.020159:0.009407:0.010079:0.019487:0.022175:0.021503:0.009407:0.018815:0.009407:0.022175:0.008063:0.022175:0.022175:0.021503:0.010079:0.021503:0.014783:0.009407:0.009407:0.020159:0.021503:0.026878:0.021503:0.010751:0.009407
drugs providing cardiovascular protection:@0.076190:0.128069:0.760243:0.128069:0.760243:0.091406:0.076190:0.091406:0.022175:0.010751:0.020159:0.022175:0.014783:0.009407:0.022175:0.010751:0.021503:0.018815:0.008063:0.022175:0.008063:0.020159:0.022175:0.009407:0.021503:0.022175:0.010751:0.022175:0.008063:0.021503:0.018815:0.022175:0.014783:0.021503:0.020159:0.008063:0.022175:0.010751:0.009407:0.022175:0.010751:0.021503:0.010079:0.021503:0.021503:0.010079:0.008063:0.021503:0.020159
P Joshi:@0.076190:0.169924:0.130619:0.169924:0.130619:0.151592:0.076190:0.151592:0.009407:0.004704:0.008063:0.010751:0.007392:0.010079:0.004032
phD FRCp FRsMed FICA MACE:@0.076190:0.181983:0.273302:0.181983:0.273302:0.167954:0.076190:0.167954:0.007956:0.008198:0.009999:0.003723:0.006518:0.008158:0.010926:0.007956:0.003723:0.006518:0.008158:0.006693:0.012351:0.008735:0.009206:0.003723:0.006518:0.003037:0.010926:0.009945:0.003723:0.012351:0.009945:0.010926:0.007203
Emeritus ad hominem Professor of Medicine, Medunsa;:@0.076190:0.199963:0.431817:0.199963:0.431817:0.185934:0.076190:0.185934:0.007203:0.012606:0.008735:0.004045:0.002688:0.004556:0.008171:0.005214:0.003723:0.009179:0.009206:0.003723:0.008198:0.008803:0.012606:0.002688:0.008198:0.008735:0.012606:0.003723:0.007956:0.004045:0.008803:0.004220:0.008735:0.005214:0.005214:0.008803:0.004045:0.003723:0.008803:0.004220:0.003723:0.012351:0.008735:0.009206:0.002688:0.008695:0.002688:0.008198:0.008735:0.003723:0.003723:0.012351:0.008735:0.009206:0.008171:0.008198:0.005214:0.009179:0.003723
Director of Diabetes Care & Clinical Trials Centre, :@0.076190:0.212812:0.398098:0.212812:0.398098:0.198783:0.076190:0.198783:0.009999:0.002688:0.004045:0.008735:0.008695:0.004556:0.008803:0.004045:0.003723:0.008803:0.004220:0.003723:0.009999:0.002688:0.009179:0.009165:0.008735:0.004556:0.008735:0.005214:0.003723:0.010926:0.009179:0.004045:0.008735:0.003723:0.010173:0.003723:0.010926:0.002688:0.002688:0.008198:0.002688:0.008695:0.009179:0.002688:0.003723:0.005725:0.004045:0.002688:0.009179:0.002688:0.005214:0.003723:0.010926:0.008735:0.008198:0.004556:0.004045:0.008735:0.003723:0.003723
Brooklyn, Pretoria:@0.076190:0.225661:0.187843:0.225661:0.187843:0.211632:0.076190:0.211632:0.007714:0.004045:0.008803:0.008803:0.006746:0.002688:0.007203:0.008198:0.003723:0.003723:0.007956:0.004045:0.008735:0.004556:0.008803:0.004045:0.002688:0.009179
Epidemiological  studies continue to show an increas-:@0.076190:0.255572:0.480942:0.255572:0.480942:0.239790:0.076190:0.239790:0.008104:0.010311:0.003024:0.010357:0.009827:0.014182:0.003024:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.010326:0.003024:0.004188:0.002903:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.007076:0.009782:0.009903:0.009223:0.005110:0.003024:0.009223:0.009192:0.009827:0.007076:0.005125:0.009903:0.007076:0.005866:0.009223:0.009903:0.012564:0.007076:0.010326:0.009223:0.007076:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.005020
ing prevalence of type 2 diabetes (T2D) nationally, re-:@0.076190:0.269704:0.480942:0.269704:0.480942:0.253921:0.076190:0.253921:0.003024:0.009223:0.010175:0.005503:0.010311:0.004551:0.009827:0.008376:0.010326:0.003024:0.009827:0.009223:0.009782:0.009827:0.005503:0.009903:0.004747:0.005503:0.005125:0.008104:0.010311:0.009827:0.005518:0.008376:0.005518:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.005503:0.005579:0.006441:0.008376:0.011249:0.005579:0.005518:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.003024:0.008104:0.004188:0.005518:0.004551:0.009827:0.005020
gionally and globally. Hitherto,  medications available :@0.076190:0.283836:0.485135:0.283832:0.485135:0.268049:0.076190:0.268053:0.010175:0.003024:0.009903:0.009223:0.010326:0.003024:0.003024:0.008104:0.006683:0.010326:0.009223:0.010357:0.006683:0.010175:0.003024:0.009903:0.010311:0.010326:0.003024:0.003024:0.008104:0.004188:0.008744:0.010326:0.003024:0.005125:0.009223:0.009827:0.004551:0.005125:0.009903:0.004188:0.004188:0.002480:0.014182:0.009827:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.006683:0.010326:0.008376:0.010326:0.003024:0.003024:0.010326:0.010326:0.003024:0.009827:0.477559
1 :@0.238351:0.278533:0.245638:0.278533:0.245638:0.269379:0.238351:0.269379:0.004858:0.002429
for its treatment have shown that tight glycaemic con-:@0.076196:0.297964:0.480947:0.297964:0.480947:0.282181:0.076196:0.282181:0.004747:0.009903:0.004551:0.004883:0.003024:0.005125:0.005866:0.004883:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004868:0.009223:0.010326:0.008376:0.009827:0.004883:0.005866:0.009223:0.009903:0.012564:0.009223:0.004883:0.005125:0.009223:0.010326:0.005125:0.004883:0.005125:0.003024:0.010175:0.009223:0.005125:0.004883:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.004899:0.009782:0.009903:0.009223:0.005020
trol bears a significant impact on reducing the micro:@0.076196:0.312095:0.475928:0.312095:0.475928:0.296313:0.076196:0.296313:0.005125:0.004551:0.009903:0.003024:0.006138:0.010311:0.009827:0.010326:0.004551:0.005866:0.006153:0.010326:0.006153:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.006153:0.003024:0.014182:0.010311:0.010326:0.009782:0.005125:0.006153:0.009903:0.009223:0.006138:0.004551:0.009827:0.010357:0.009192:0.009782:0.003024:0.009223:0.010175:0.006138:0.005125:0.009223:0.009827:0.006138:0.014182:0.003024:0.009782:0.004551:0.009903
-:@0.475928:0.312095:0.480947:0.312095:0.480947:0.296313:0.475928:0.296313:0.005020
vascular complications of the disease. However, these :@0.076196:0.326227:0.485151:0.326227:0.485151:0.310444:0.076196:0.310444:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005382:0.009782:0.009903:0.014182:0.010311:0.003024:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.005382:0.009903:0.004747:0.005367:0.005125:0.009223:0.009827:0.005367:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.005443:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.005367:0.005125:0.009223:0.009827:0.005866:0.009827:0.004188
 :@0.360721:0.326227:0.364954:0.326227:0.364954:0.309728:0.360721:0.309728:0.004233
benefits have not been revealed in the development of :@0.076196:0.340359:0.485151:0.340359:0.485151:0.324576:0.076196:0.324576:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.003598:0.009223:0.010326:0.008376:0.009827:0.003613:0.009223:0.009903:0.005125:0.003598:0.010311:0.009827:0.009827:0.009223:0.003613:0.004551:0.009827:0.008376:0.009827:0.010326:0.003024:0.009827:0.010357:0.003613:0.003024:0.009223:0.003613:0.005125:0.009223:0.009827:0.003598:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.003613:0.009903:0.004747:0.004188
macrovascular disease even when stringent glycaemic :@0.076196:0.354490:0.485135:0.354490:0.485135:0.338708:0.076196:0.338708:0.014182:0.010326:0.009782:0.004551:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004203:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004218:0.009827:0.008376:0.009827:0.009223:0.004203:0.012564:0.009223:0.009827:0.009223:0.004203:0.005866:0.005125:0.004551:0.003024:0.009223:0.010175:0.009827:0.009223:0.005125:0.004188:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.004188
control was achieved.  It is well known that the major :@0.076196:0.368622:0.485142:0.368611:0.485142:0.352828:0.076196:0.352839:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.006032:0.012564:0.010326:0.005866:0.006048:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.010357:0.004188:0.004845:0.006032:0.003417:0.005125:0.006032:0.003024:0.005866:0.006048:0.012564:0.009827:0.003024:0.003024:0.006048:0.007590:0.009223:0.009903:0.012564:0.009223:0.006032:0.005125:0.009223:0.010326:0.005125:0.006032:0.005125:0.009223:0.009827:0.006032:0.014182:0.010326:0.003069:0.009903:0.004551:0.366533
4:@0.243458:0.363312:0.248316:0.363312:0.248316:0.354158:0.243458:0.354158:0.004858
causes of  morbidity and mortality ensue from  macro-:@0.076188:0.382742:0.480954:0.382742:0.480954:0.366960:0.076188:0.366960:0.009782:0.010326:0.009192:0.005866:0.009827:0.005866:0.006622:0.009903:0.004747:0.004188:0.002419:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.006622:0.010326:0.009223:0.010357:0.006622:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.006622:0.009827:0.009223:0.005866:0.009192:0.009827:0.006622:0.004747:0.004551:0.009903:0.014182:0.004188:0.002419:0.014182:0.010326:0.009782:0.004551:0.009903:0.005020
vascular disease. In some  instances, drugs  aiming to :@0.076188:0.396874:0.485142:0.396874:0.485142:0.381091:0.076188:0.381091:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.007726:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.007726:0.003417:0.009223:0.007726:0.005866:0.009903:0.014182:0.009827:0.004188:0.003523:0.003024:0.009223:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.005866:0.004188:0.007726:0.010357:0.004551:0.009192:0.010175:0.005866:0.004188:0.003523:0.010326:0.003024:0.014182:0.003024:0.009223:0.010175:0.007726:0.005125:0.009903:0.004188
achieve better glycaemic control even resulted in an :@0.076188:0.411006:0.485127:0.411006:0.485127:0.395223:0.076188:0.395223:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.006153:0.010311:0.009827:0.005125:0.005125:0.009827:0.004536:0.006153:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.006153:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.006138:0.009827:0.008376:0.009827:0.009223:0.006153:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.009827:0.010357:0.006153:0.003024:0.009223:0.006153:0.010326:0.009223:0.004188
increased risk of cardiovascular disease – for example,:@0.076188:0.425137:0.480954:0.425137:0.480954:0.409355:0.076188:0.409355:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.005156:0.004551:0.003024:0.005866:0.007590:0.005156:0.009903:0.004747:0.005156:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005171:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005171:0.007560:0.005156:0.004747:0.009903:0.004551:0.005156:0.009827:0.007257:0.010326:0.014182:0.010311:0.003024:0.009827:0.004188
 :@0.480954:0.425137:0.485188:0.425137:0.485188:0.408639:0.480954:0.408639:0.004233
rosiglitazone was very effective in attaining glycaemic :@0.076188:0.439269:0.485112:0.439269:0.485112:0.423486:0.076188:0.423486:0.004551:0.009903:0.005866:0.003024:0.010175:0.003024:0.003024:0.005125:0.010326:0.006426:0.009903:0.009223:0.009827:0.005564:0.012564:0.010326:0.005866:0.005579:0.008376:0.009827:0.004551:0.008104:0.005564:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.005564:0.003024:0.009223:0.005564:0.010326:0.005125:0.005125:0.010326:0.003024:0.009223:0.003024:0.009223:0.010175:0.005564:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.004188
control, but resulted in increased cardiovascular com-:@0.076188:0.453400:0.480954:0.453400:0.480954:0.437618:0.076188:0.437618:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.004188:0.005549:0.010311:0.009192:0.005125:0.005564:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.009827:0.010357:0.005564:0.003024:0.009223:0.005564:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.005564:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005564:0.009782:0.009903:0.014182:0.005020
plications. This is our modern-day challenge. Over two-:@0.076188:0.467532:0.480939:0.467532:0.480939:0.451749:0.076188:0.451749:0.010311:0.003024:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004989:0.006441:0.009223:0.003024:0.005866:0.004989:0.003024:0.005866:0.004989:0.009903:0.009192:0.004551:0.004974:0.014182:0.009903:0.010357:0.009827:0.004551:0.009223:0.005020:0.010341:0.010326:0.008104:0.004989:0.009782:0.009223:0.010326:0.003024:0.003024:0.009827:0.009223:0.010175:0.009827:0.004188:0.004989:0.013138:0.008376:0.009827:0.004551:0.004989:0.005125:0.012564:0.009903:0.005020
thirds of patients die from cardiovascular disease, and :@0.076188:0.481664:0.485142:0.481664:0.485142:0.465881:0.076188:0.465881:0.005125:0.009223:0.003024:0.004551:0.010357:0.005866:0.005428:0.009903:0.004747:0.005428:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005428:0.010357:0.003024:0.009827:0.005428:0.004747:0.004551:0.009903:0.014182:0.005413:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005428:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.005428:0.010326:0.009223:0.010357:0.004188
stroke rates are unacceptably high, being two to four :@0.076188:0.495795:0.485142:0.495795:0.485142:0.480013:0.076188:0.480013:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.005836:0.004551:0.010326:0.005125:0.009827:0.005866:0.005851:0.010326:0.004551:0.009827:0.005851:0.009192:0.009223:0.010326:0.009782:0.009782:0.009827:0.010311:0.005125:0.010326:0.010311:0.003024:0.008104:0.005851:0.009223:0.003024:0.010175:0.009223:0.004188:0.005836:0.010311:0.009827:0.003024:0.009223:0.010175:0.005851:0.005125:0.012564:0.009903:0.005851:0.005125:0.009903:0.005836:0.004747:0.009903:0.009192:0.004551:0.004188
times higher, compared to the general population.  :@0.076188:0.509927:0.458482:0.509908:0.458482:0.494126:0.076188:0.494144:0.005125:0.003024:0.014182:0.009827:0.005866:0.004188:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.004188:0.004188:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004188:0.005125:0.009903:0.004188:0.005125:0.009223:0.009827:0.004188:0.010175:0.009827:0.009223:0.009827:0.004551:0.010326:0.003024:0.004188:0.010311:0.009903:0.010311:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004817:0.208160
2:@0.449434:0.504610:0.454292:0.504610:0.454292:0.495456:0.449434:0.495456:0.004858
In 2008 the Us FDA and the EMA mandated that spon-:@0.090469:0.524040:0.480949:0.524040:0.480949:0.508257:0.090469:0.508257:0.003417:0.009223:0.003583:0.008376:0.008376:0.008376:0.008376:0.003598:0.005125:0.009223:0.009827:0.003583:0.009903:0.007529:0.003583:0.007333:0.011249:0.011188:0.003583:0.010326:0.009223:0.010357:0.003583:0.005125:0.009223:0.009827:0.003583:0.008104:0.013894:0.011188:0.003583:0.014182:0.010326:0.009223:0.010357:0.010326:0.005125:0.009827:0.010357:0.003583:0.005125:0.009223:0.010326:0.005125:0.003583:0.005866:0.010311:0.009903:0.009223:0.005020
sors of new glucose-lowering therapies should demon-:@0.076182:0.538172:0.480964:0.538172:0.480964:0.522389:0.076182:0.522389:0.005866:0.009903:0.004551:0.005866:0.005518:0.009903:0.004747:0.005518:0.009223:0.009827:0.012564:0.005518:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.005020:0.003024:0.009903:0.012564:0.009827:0.004551:0.003024:0.009223:0.010175:0.005503:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.003024:0.009827:0.005866:0.005518:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.005518:0.010357:0.009827:0.014182:0.009903:0.009223:0.005020
strate that therapy would not result in an unacceptable :@0.076182:0.552303:0.485137:0.552303:0.485137:0.536521:0.076182:0.536521:0.005866:0.005125:0.004551:0.010326:0.005125:0.009827:0.003870:0.005125:0.009223:0.010326:0.005125:0.003870:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.003870:0.012564:0.009903:0.009192:0.003024:0.010357:0.003870:0.009223:0.009903:0.005125:0.003855:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.003870:0.003024:0.009223:0.003870:0.010326:0.009223:0.003870:0.009192:0.009223:0.010326:0.009782:0.009782:0.009827:0.010311:0.005125:0.010326:0.010311:0.003024:0.009827:0.004188
increase in cardiovascular  risk.  Hence, newer agents :@0.076182:0.566435:0.485149:0.566427:0.485149:0.550645:0.076182:0.550652:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.006819:0.003024:0.009223:0.006819:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.002646:0.004551:0.003024:0.005866:0.007590:0.004188:0.004865:0.006819:0.010326:0.009827:0.009223:0.009782:0.009827:0.004188:0.006819:0.009223:0.009827:0.012564:0.009827:0.004551:0.006819:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.107481
3:@0.305936:0.561129:0.310794:0.561129:0.310794:0.551975:0.305936:0.551975:0.004858
have been tested in a number of cardiovascular out-:@0.076194:0.580559:0.480961:0.580559:0.480961:0.564776:0.076194:0.564776:0.009223:0.010326:0.008376:0.009827:0.006078:0.010311:0.009827:0.009827:0.009223:0.006063:0.005125:0.009827:0.005866:0.005125:0.009827:0.010357:0.006063:0.003024:0.009223:0.006078:0.010326:0.006078:0.009223:0.009192:0.014182:0.010311:0.009827:0.004551:0.006063:0.009903:0.004747:0.006063:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.006078:0.009903:0.009192:0.005125:0.005020
comes trials (CVOT).:@0.076194:0.594691:0.223877:0.594691:0.223877:0.578908:0.076194:0.578908:0.009782:0.009903:0.014182:0.009827:0.005866:0.004188:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004188:0.005579:0.012292:0.010614:0.013138:0.006441:0.005579:0.004188
These newer agents include the following classes of :@0.090482:0.608822:0.485134:0.608822:0.485134:0.593040:0.090482:0.593040:0.006441:0.009223:0.009827:0.005866:0.009827:0.006184:0.009223:0.009827:0.012564:0.009827:0.004551:0.006184:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.006184:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.006199:0.005125:0.009223:0.009827:0.006184:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.003024:0.009223:0.010175:0.006199:0.009782:0.003024:0.010326:0.005866:0.005866:0.009827:0.005866:0.006214:0.009903:0.004747:0.004188
drugs: Dpp-4 inhibitors, GLp-1 receptor  agonists, and :@0.076194:0.622954:0.485134:0.622954:0.485134:0.607171:0.076194:0.607171:0.010357:0.004551:0.009192:0.010175:0.005866:0.004188:0.008406:0.011249:0.008950:0.008950:0.005020:0.008376:0.008406:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.008406:0.013184:0.006985:0.008950:0.005020:0.008376:0.008406:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.004188:0.004203:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.005866:0.004188:0.008406:0.010326:0.009223:0.010357:0.004188
sGLT2 Inhibitors. The introduction of these drugs has in-:@0.076194:0.637085:0.480961:0.637085:0.480961:0.621303:0.076194:0.621303:0.007529:0.013184:0.006985:0.006441:0.008376:0.005397:0.003417:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.005397:0.006441:0.009223:0.009827:0.005382:0.003024:0.009223:0.005125:0.004551:0.009903:0.010357:0.009192:0.009782:0.005110:0.003024:0.009903:0.009223:0.005397:0.009903:0.004747:0.005397:0.005125:0.009223:0.009827:0.005866:0.009827:0.005382:0.010357:0.004551:0.009192:0.010175:0.005866:0.005397:0.009223:0.010326:0.005866:0.005397:0.003024:0.009223:0.005020
fluenced  national  and  international  guidelines  for  the :@0.076194:0.651217:0.485164:0.651217:0.485164:0.635434:0.076194:0.635434:0.003666:0.003666:0.009192:0.009827:0.009223:0.009782:0.009827:0.010357:0.004188:0.002525:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.004188:0.002540:0.010326:0.009223:0.010357:0.004188:0.002540:0.003024:0.009223:0.005125:0.009827:0.004551:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.004188:0.002525:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.004188:0.002540:0.004747:0.009903:0.004551:0.004188:0.002525:0.005125:0.009223:0.009827:0.004188
current treatment of type 2 diabetes.:@0.076194:0.665349:0.347944:0.665349:0.347944:0.649566:0.076194:0.649566:0.009782:0.009192:0.004551:0.004551:0.009827:0.009223:0.005125:0.004188:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.009903:0.004747:0.004188:0.005125:0.008104:0.010311:0.009827:0.004188:0.008376:0.004188:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188
The impact of intensive therapy in diabetes in major :@0.090482:0.679480:0.485164:0.679480:0.485164:0.663698:0.090482:0.663698:0.006441:0.009223:0.009827:0.005670:0.003024:0.014182:0.010311:0.010326:0.009782:0.005125:0.005685:0.009903:0.004747:0.005670:0.003024:0.009223:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.005685:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.005670:0.003024:0.009223:0.005685:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.005685:0.003024:0.009223:0.005685:0.014182:0.010326:0.003069:0.009903:0.004551:0.004188
clinical trials, such as the DCCT/EDIC in T1D, and the T2D :@0.076194:0.693612:0.485134:0.693612:0.485134:0.677829:0.076194:0.677829:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.003659:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004188:0.003644:0.005866:0.009192:0.009782:0.009223:0.003644:0.010326:0.005866:0.003644:0.005125:0.009223:0.009827:0.003629:0.011249:0.012292:0.012292:0.006441:0.006607:0.008104:0.011249:0.003417:0.012292:0.003644:0.003024:0.009223:0.003644:0.006441:0.008376:0.011249:0.004188:0.003644:0.010326:0.009223:0.010357:0.003644:0.005125:0.009223:0.009827:0.003629:0.006441:0.008376:0.011249:0.004188
studies, including the UKpDs, ACCORD, ADVANCE and :@0.076194:0.707744:0.485149:0.707744:0.485149:0.691961:0.076194:0.691961:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188:0.005020:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.003024:0.009223:0.010175:0.005020:0.005125:0.009223:0.009827:0.005020:0.009903:0.008935:0.008950:0.011249:0.007529:0.004188:0.005020:0.011188:0.012292:0.012292:0.013138:0.009177:0.011249:0.004188:0.005020:0.011188:0.011249:0.010614:0.011188:0.011188:0.012292:0.008104:0.005020:0.010326:0.009223:0.010357:0.004188
VADT,  have  all  uniformly  shown  benefits  for  microvas:@0.076194:0.721875:0.475941:0.721875:0.475941:0.706093:0.076194:0.706093:0.010614:0.011188:0.011249:0.006441:0.004188:0.004188:0.002449:0.009223:0.010326:0.008376:0.009827:0.004188:0.002449:0.010326:0.003024:0.003024:0.004188:0.002449:0.009192:0.009223:0.003024:0.004747:0.009903:0.004551:0.014182:0.003024:0.008104:0.004188:0.002449:0.005866:0.009223:0.009903:0.012564:0.009223:0.004188:0.002449:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.004188:0.002449:0.004747:0.009903:0.004551:0.004188:0.002449:0.014182:0.003024:0.009782:0.004551:0.009903:0.008376:0.010326:0.005866
-:@0.475941:0.721875:0.480961:0.721875:0.480961:0.706093:0.475941:0.706093:0.005020
cular disease, but not for macrovascular disease (see :@0.076194:0.736007:0.485149:0.736007:0.485149:0.720224:0.076194:0.720224:0.009782:0.009192:0.003024:0.010326:0.004551:0.006305:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.006305:0.010311:0.009192:0.005125:0.006305:0.009223:0.009903:0.005125:0.006305:0.004747:0.009903:0.004551:0.006305:0.014182:0.010326:0.009782:0.004551:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.006305:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.006320:0.005579:0.005866:0.009827:0.009827:0.004188
Table 1).:@0.076194:0.750138:0.138454:0.750138:0.138454:0.734356:0.076194:0.734356:0.006441:0.010326:0.010311:0.003024:0.009827:0.004188:0.008376:0.005579:0.004188
4:@0.138453:0.744816:0.143311:0.744816:0.143311:0.735662:0.138453:0.735662:0.004858
However,  long-term  follow-up  yielded some  reduc-:@0.533333:0.168568:0.923812:0.168568:0.923812:0.152785:0.533333:0.152785:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.004188:0.003644:0.003024:0.009903:0.009223:0.010175:0.005020:0.005125:0.009827:0.004551:0.014182:0.004188:0.003644:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.005020:0.009192:0.010311:0.004188:0.003644:0.008104:0.003024:0.009827:0.003024:0.010357:0.009827:0.010357:0.007847:0.005866:0.009903:0.014182:0.009827:0.004188:0.003644:0.004551:0.009827:0.010357:0.009192:0.009782:0.005020
tions in cardiovascular disease and mortality in the UKp-:@0.519045:0.183588:0.923812:0.183588:0.923812:0.167806:0.519045:0.167806:0.005125:0.003024:0.009903:0.009223:0.005866:0.004052:0.003024:0.009223:0.004052:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004052:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009842:0.004052:0.010326:0.009223:0.010357:0.004052:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004052:0.003024:0.009223:0.004052:0.005125:0.009223:0.009827:0.004037:0.009903:0.008935:0.008935:0.005020
Ds, and reduction in cardiovascular disease in the VADT :@0.519045:0.198609:0.928000:0.198609:0.928000:0.182826:0.519045:0.182826:0.011249:0.007529:0.004188:0.003538:0.010326:0.009223:0.010357:0.003538:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.003523:0.003024:0.009223:0.003538:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.003538:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.003538:0.003024:0.009223:0.003538:0.005125:0.009223:0.009827:0.003523:0.010614:0.011188:0.011249:0.006441:0.004188
study (see Table 1).:@0.519045:0.213630:0.659426:0.213630:0.659426:0.197847:0.519045:0.197847:0.005866:0.005125:0.009192:0.010357:0.008104:0.004188:0.005579:0.005866:0.009827:0.009827:0.004188:0.006441:0.010326:0.010311:0.003024:0.009827:0.004188:0.008376:0.005579:0.004188
lOnGer-ACtinG bAsAl insulins:@0.519047:0.247376:0.813230:0.247376:0.813230:0.227211:0.519047:0.227211:0.008131:0.015522:0.013674:0.015522:0.009609:0.010718:0.007761:0.013674:0.014413:0.007761:0.005174:0.013674:0.015522:0.005174:0.010718:0.013674:0.009609:0.013674:0.008131:0.005174:0.005174:0.013674:0.009609:0.011826:0.008131:0.005174:0.013674:0.009609
The ORIGIN study (Outcome Reduction with Initial Glar-:@0.519047:0.264169:0.923814:0.264169:0.923814:0.248386:0.519047:0.248386:0.006441:0.009223:0.009827:0.004264:0.013138:0.009177:0.003417:0.013184:0.003417:0.011188:0.004279:0.007529:0.005125:0.009192:0.010357:0.008104:0.004279:0.005579:0.013138:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.004264:0.009177:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004264:0.012564:0.003024:0.005125:0.009223:0.004279:0.003417:0.009223:0.003024:0.005125:0.003024:0.010326:0.003024:0.004279:0.013184:0.003024:0.010326:0.004551:0.005020
gine Intervention) was a large randomised control study :@0.519047:0.279189:0.927972:0.279189:0.927972:0.263407:0.519047:0.263407:0.010175:0.003024:0.009223:0.009827:0.003613:0.003417:0.009223:0.005125:0.009827:0.004551:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.005579:0.003644:0.012564:0.010326:0.005866:0.003613:0.010326:0.003613:0.003024:0.010326:0.004551:0.010175:0.009827:0.003613:0.004551:0.010326:0.009223:0.010357:0.009903:0.014182:0.003024:0.005866:0.009827:0.010357:0.003613:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.003598:0.005866:0.005125:0.009192:0.010357:0.008104:0.004188
 :@0.647317:0.279189:0.651550:0.279189:0.651550:0.262691:0.647317:0.262691:0.004233
(RCT) with over 12 600 subjects. It recruited patients with :@0.519047:0.294210:0.927987:0.294210:0.927987:0.278427:0.519047:0.278427:0.005579:0.009177:0.012292:0.006441:0.005579:0.003825:0.012564:0.003024:0.005125:0.009223:0.003825:0.009903:0.008376:0.009827:0.004551:0.003825:0.008376:0.008376:0.003840:0.008376:0.008376:0.008376:0.003840:0.005866:0.009192:0.010311:0.003069:0.009827:0.009782:0.005125:0.005866:0.004188:0.003825:0.003417:0.005125:0.003825:0.004551:0.009827:0.009782:0.004551:0.009192:0.003024:0.005125:0.009827:0.010357:0.003810:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003825:0.012564:0.003024:0.005125:0.009223:0.004188
new or recent diabetes, impaired fasting glucose (IFG) :@0.519047:0.309231:0.927987:0.309231:0.927987:0.293448:0.519047:0.293448:0.009223:0.009827:0.012564:0.004929:0.009903:0.004551:0.004929:0.004551:0.009827:0.009782:0.009827:0.009223:0.005125:0.004929:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.004944:0.003024:0.014182:0.010311:0.010326:0.003024:0.004551:0.009827:0.010357:0.004944:0.004747:0.010326:0.005866:0.005125:0.003024:0.009223:0.010175:0.004944:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.004929:0.005579:0.003417:0.007333:0.013184:0.005579:0.004188
or  impaired  glucose  tolerance  (IGT) and  additional :@0.519047:0.324251:0.927972:0.324251:0.927972:0.308469:0.519047:0.308469:0.009903:0.004551:0.004188:0.005231:0.003024:0.014182:0.010311:0.010326:0.003024:0.004551:0.009827:0.010357:0.004188:0.005231:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.004188:0.005231:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.009223:0.009782:0.009827:0.004188:0.005231:0.005579:0.003417:0.013184:0.006441:0.005579:0.009434:0.010326:0.009223:0.010357:0.004188:0.005231:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.004188
cardio vascular-risk factors. One of its aims was to de-:@0.519047:0.339272:0.923799:0.339272:0.923799:0.323489:0.519047:0.323489:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.000000:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005020:0.004551:0.003024:0.005866:0.007590:0.006456:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.004188:0.006441:0.013138:0.009223:0.009827:0.006441:0.009903:0.004747:0.006441:0.003024:0.005125:0.005866:0.006456:0.010326:0.003024:0.014182:0.005866:0.006456:0.012564:0.010326:0.005866:0.006456:0.005125:0.009903:0.006441:0.010357:0.009827:0.005020
termine if insulin  glargine-mediated normoglycaemia :@0.519047:0.354293:0.928002:0.354293:0.928002:0.338510:0.519047:0.338510:0.005125:0.009827:0.004551:0.014182:0.003024:0.009223:0.009827:0.008436:0.003024:0.004747:0.008436:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.004188:0.004264:0.010175:0.003024:0.010326:0.004551:0.010175:0.003024:0.009223:0.009827:0.005020:0.014182:0.009827:0.010357:0.003024:0.010326:0.005125:0.009827:0.010357:0.008436:0.009223:0.009903:0.004551:0.014182:0.009903:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.010326:0.004188
can reduce cardiovascular morbidity and/or mortality :@0.519047:0.369313:0.928002:0.369313:0.928002:0.353531:0.519047:0.353531:0.009782:0.010326:0.009223:0.005927:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.005912:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005927:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.005927:0.010326:0.009223:0.010357:0.006607:0.009903:0.004551:0.005912:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188
in high-risk cardiovascular disease with IFG, IGT, or early :@0.519047:0.384334:0.927972:0.384334:0.927972:0.368551:0.519047:0.368551:0.003024:0.009223:0.004339:0.009223:0.003024:0.010175:0.009223:0.005020:0.004551:0.003024:0.005866:0.007590:0.004339:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004354:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004354:0.012564:0.003024:0.005125:0.009223:0.004339:0.003417:0.007333:0.013184:0.004188:0.004339:0.003417:0.013184:0.006441:0.004188:0.004339:0.009903:0.004551:0.004339:0.009827:0.010326:0.004551:0.003024:0.008104:0.004188
T2D in patients aged ≥50 years with dysglycaemia and :@0.519047:0.399354:0.928017:0.399354:0.928017:0.383572:0.519047:0.383572:0.006441:0.008376:0.011249:0.005035:0.003024:0.009223:0.005035:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005035:0.010326:0.010175:0.009827:0.010357:0.005035:0.008300:0.008376:0.008376:0.005035:0.008104:0.009827:0.010326:0.004551:0.005866:0.005035:0.012564:0.003024:0.005125:0.009223:0.005035:0.010357:0.008104:0.005866:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.010326:0.005050:0.010326:0.009223:0.010357:0.004188
at high cardiovascular risk.:@0.519047:0.414375:0.713312:0.414375:0.713312:0.398592:0.519047:0.398592:0.010326:0.005125:0.004188:0.009223:0.003024:0.010175:0.009223:0.004188:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.004551:0.003024:0.005866:0.007590:0.004188
 :@0.713312:0.414375:0.717545:0.414375:0.717545:0.397877:0.713312:0.397877:0.004233
The study conclusions were that when used to target :@0.533335:0.429396:0.928002:0.429396:0.928002:0.413613:0.533335:0.413613:0.006441:0.009223:0.009827:0.004838:0.005866:0.005125:0.009192:0.010357:0.008104:0.004853:0.009782:0.009903:0.009223:0.009782:0.003024:0.009192:0.005866:0.003024:0.009903:0.009223:0.005866:0.004853:0.012564:0.009827:0.004551:0.009827:0.004838:0.005125:0.009223:0.010326:0.005125:0.004838:0.012564:0.009223:0.009827:0.009223:0.004838:0.009192:0.005866:0.009827:0.010357:0.004853:0.005125:0.009903:0.004838:0.005125:0.010326:0.004551:0.010175:0.009827:0.005125:0.004188
normal  fasting glucose  levels for  more  than  six years, :@0.519047:0.444416:0.927987:0.444416:0.927987:0.428634:0.519047:0.428634:0.009223:0.009903:0.004551:0.014182:0.010326:0.003024:0.004188:0.002903:0.004747:0.010326:0.005866:0.005125:0.003024:0.009223:0.010175:0.007106:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.004188:0.002903:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.007106:0.004747:0.009903:0.004551:0.004188:0.002903:0.014182:0.009903:0.004551:0.009827:0.004188:0.002903:0.005125:0.009223:0.010326:0.009223:0.004188:0.002903:0.005866:0.003024:0.007257:0.007106:0.008104:0.009827:0.010326:0.004551:0.005866:0.004188:0.004188
insulin glargine had a neutral effect on cardiovascular :@0.519047:0.459437:0.928002:0.459437:0.928002:0.443654:0.519047:0.443654:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.005413:0.010175:0.003024:0.010326:0.004551:0.010175:0.003024:0.009223:0.009827:0.005397:0.009223:0.010326:0.010357:0.005397:0.010326:0.005397:0.009223:0.009827:0.009192:0.005125:0.004551:0.010326:0.003024:0.005397:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005397:0.009903:0.009223:0.005397:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
outcomes.:@0.519047:0.474458:0.597016:0.474458:0.597016:0.458675:0.519047:0.458675:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.004188
5:@0.597005:0.469083:0.601863:0.469083:0.601863:0.459929:0.597005:0.459929:0.004858
The DEVOTE (Efficacy and Safety of Degludec :@0.533333:0.489397:0.879030:0.489397:0.879030:0.473614:0.533333:0.473614:0.006290:0.009071:0.009676:0.006063:0.011097:0.007953:0.010462:0.012987:0.006290:0.007953:0.006063:0.005428:0.007953:0.004596:0.003606:0.003606:0.009631:0.010175:0.009631:0.007953:0.006063:0.010175:0.009071:0.010205:0.006063:0.007378:0.010175:0.004596:0.009676:0.004974:0.007953:0.006063:0.009752:0.004596:0.006063:0.011097:0.009676:0.010024:0.002873:0.009041:0.010205:0.009676:0.009631:0.004188
versus:@0.880889:0.489397:0.923812:0.489397:0.923812:0.473614:0.880889:0.473614:0.008225:0.009676:0.004400:0.005715:0.009041:0.005866
 :@0.923812:0.489397:0.928000:0.489397:0.928000:0.473614:0.923812:0.473614:0.004188
Glargine in Type 2 Diabetes) was another long-term, :@0.519045:0.504417:0.928031:0.504417:0.928031:0.488635:0.519045:0.488635:0.013033:0.002873:0.010175:0.004400:0.010024:0.002873:0.009071:0.009676:0.008482:0.002873:0.009071:0.008482:0.006290:0.007953:0.010160:0.009676:0.008482:0.008225:0.008482:0.011097:0.002873:0.010175:0.010160:0.009676:0.004974:0.009676:0.005715:0.005428:0.008482:0.012413:0.010175:0.005715:0.008482:0.010175:0.009071:0.009752:0.004974:0.009071:0.009676:0.004400:0.008482:0.002873:0.009752:0.009071:0.010024:0.004868:0.004974:0.009676:0.004400:0.014030:0.004188:0.004188
multinational study that looked at cardiovascular safety :@0.519045:0.519438:0.928000:0.519438:0.928000:0.503655:0.519045:0.503655:0.014030:0.009041:0.002873:0.004974:0.002873:0.009071:0.010175:0.004974:0.002873:0.009752:0.009071:0.010175:0.002873:0.004929:0.005715:0.004974:0.009041:0.010205:0.007953:0.004929:0.004974:0.009071:0.010175:0.004974:0.004929:0.002873:0.009752:0.009752:0.007439:0.009676:0.010205:0.004929:0.010175:0.004974:0.004929:0.009631:0.010175:0.004400:0.010205:0.002873:0.009752:0.008225:0.010175:0.005715:0.009631:0.009041:0.002873:0.010175:0.004400:0.004929:0.005715:0.010175:0.004596:0.009676:0.004974:0.008104:0.004188
during treatment with insulin degludec, compared with :@0.519045:0.534459:0.928000:0.534459:0.928000:0.518676:0.519045:0.518676:0.010205:0.009041:0.004400:0.002873:0.009071:0.010024:0.005579:0.004974:0.004400:0.009676:0.010175:0.004974:0.014030:0.009676:0.009071:0.004974:0.005579:0.012413:0.002873:0.004974:0.009071:0.005579:0.002873:0.009071:0.005715:0.009041:0.002873:0.002873:0.009071:0.005579:0.010205:0.009676:0.010024:0.002873:0.009041:0.010205:0.009676:0.009631:0.004037:0.005579:0.009631:0.009752:0.014030:0.010160:0.010175:0.004400:0.009676:0.010205:0.005579:0.012413:0.002873:0.004974:0.009223:0.004188
insulin glargine U-100, in people with T2D who are at high :@0.519045:0.549479:0.927970:0.549479:0.927970:0.533697:0.519045:0.533697:0.002873:0.009071:0.005715:0.009041:0.002873:0.002873:0.009071:0.003976:0.010024:0.002873:0.010175:0.004400:0.010024:0.002873:0.009071:0.009676:0.003976:0.009752:0.004868:0.008225:0.008225:0.008225:0.004037:0.003976:0.002873:0.009071:0.003976:0.010160:0.009676:0.009752:0.010160:0.002873:0.009676:0.003976:0.012413:0.002873:0.004974:0.009071:0.003976:0.006290:0.008225:0.011097:0.003976:0.012413:0.009071:0.009752:0.003976:0.010175:0.004400:0.009676:0.003976:0.010175:0.004974:0.003976:0.009071:0.002873:0.010024:0.009223:0.004188
risk of cardiovascular diseases. participants were aged :@0.519045:0.564500:0.928015:0.564500:0.928015:0.548717:0.519045:0.548717:0.004400:0.002873:0.005715:0.007439:0.006456:0.009752:0.004596:0.006456:0.009631:0.010175:0.004400:0.010205:0.002873:0.009752:0.008225:0.010175:0.005715:0.009631:0.009041:0.002873:0.010175:0.004400:0.006456:0.010205:0.002873:0.005715:0.009676:0.010175:0.005715:0.009676:0.005715:0.004037:0.006456:0.008799:0.010175:0.004400:0.004974:0.002873:0.009631:0.002873:0.010160:0.010175:0.009071:0.004974:0.005715:0.006456:0.012413:0.009676:0.004400:0.009676:0.006456:0.010175:0.010024:0.009676:0.010357:0.004188
50 years or above, had T2D, and either heart disease or :@0.519045:0.579521:0.928015:0.579521:0.928015:0.563738:0.519045:0.563738:0.008225:0.008225:0.004838:0.007953:0.009676:0.010175:0.004400:0.005715:0.004838:0.009752:0.004400:0.004838:0.010175:0.010160:0.009752:0.008225:0.009676:0.004037:0.004838:0.009071:0.010175:0.010205:0.004838:0.006290:0.008225:0.011097:0.004037:0.004838:0.010175:0.009071:0.010205:0.004838:0.009676:0.002873:0.004974:0.009071:0.009676:0.004400:0.004838:0.009071:0.009676:0.010175:0.004400:0.004974:0.004838:0.010205:0.002873:0.005715:0.009676:0.010175:0.005715:0.009676:0.004838:0.009752:0.004551:0.004188
a high risk of heart disease. subjects were randomly di-:@0.519045:0.594541:0.923827:0.594541:0.923827:0.578759:0.519045:0.578759:0.010175:0.005579:0.009071:0.002873:0.010024:0.009071:0.005579:0.004400:0.002873:0.005715:0.007439:0.005579:0.009752:0.004596:0.005579:0.009071:0.009676:0.010175:0.004400:0.004974:0.005579:0.010205:0.002873:0.005715:0.009676:0.010175:0.005715:0.009676:0.004037:0.005579:0.007378:0.009041:0.010160:0.002918:0.009676:0.009631:0.004974:0.005715:0.005579:0.012413:0.009676:0.004400:0.009676:0.005579:0.004400:0.010175:0.009071:0.010205:0.009752:0.014030:0.002873:0.007953:0.005579:0.010205:0.002873:0.005020
vided into two groups and received either insulin deglu-:@0.519045:0.609562:0.923827:0.609562:0.923827:0.593779:0.519045:0.593779:0.008225:0.002873:0.010205:0.009676:0.010205:0.004732:0.002873:0.009071:0.004974:0.009752:0.004732:0.004974:0.012413:0.009752:0.004732:0.010024:0.004400:0.009752:0.009041:0.010160:0.005715:0.004732:0.010175:0.009071:0.010205:0.004732:0.004400:0.009676:0.009631:0.009676:0.002873:0.008225:0.009676:0.010205:0.004732:0.009676:0.002873:0.004974:0.009071:0.009676:0.004400:0.004732:0.002873:0.009071:0.005715:0.009041:0.002873:0.002873:0.009071:0.004732:0.010205:0.009676:0.010024:0.002873:0.009041:0.005020
dec or insulin glargine (in addition to their usual diabetes :@0.519045:0.624582:0.927940:0.624582:0.927940:0.608800:0.519045:0.608800:0.010205:0.009676:0.009631:0.004082:0.009752:0.004400:0.004082:0.002873:0.009071:0.005715:0.009041:0.002873:0.002873:0.009071:0.004082:0.010024:0.002873:0.010175:0.004400:0.010024:0.002873:0.009071:0.009676:0.004082:0.005428:0.002873:0.009071:0.004082:0.010175:0.010205:0.010205:0.002873:0.004974:0.002873:0.009752:0.009071:0.004082:0.004974:0.009752:0.004082:0.004974:0.009071:0.009676:0.002873:0.004400:0.004082:0.009041:0.005715:0.009041:0.010175:0.002873:0.004082:0.010205:0.002873:0.010175:0.010160:0.009676:0.004974:0.009676:0.005866:0.004188
care). This study demonstrated that degludec was non-:@0.519045:0.639603:0.923858:0.639603:0.923858:0.623820:0.519045:0.623820:0.009631:0.010175:0.004400:0.009676:0.005428:0.004037:0.005004:0.006290:0.009071:0.002873:0.005715:0.005004:0.005715:0.004974:0.009041:0.010205:0.007953:0.005004:0.010205:0.009676:0.014030:0.009752:0.009071:0.005715:0.004974:0.004400:0.010175:0.004974:0.009676:0.010205:0.005004:0.004974:0.009071:0.010175:0.004974:0.005004:0.010205:0.009676:0.010024:0.002873:0.009041:0.010205:0.009676:0.009631:0.005004:0.012413:0.010175:0.005715:0.005004:0.009071:0.009752:0.009071:0.005020
inferior to insulin glargine U100 with regard to the primary :@0.519045:0.654624:0.928061:0.654624:0.928061:0.638841:0.519045:0.638841:0.002873:0.009071:0.004596:0.009676:0.004400:0.002873:0.009752:0.004400:0.004067:0.004974:0.009752:0.004067:0.002873:0.009071:0.005715:0.009041:0.002873:0.002873:0.009071:0.004067:0.010024:0.002873:0.010175:0.004400:0.010024:0.002873:0.009071:0.009676:0.004067:0.009752:0.008225:0.008225:0.008225:0.004067:0.012413:0.002873:0.004974:0.009071:0.004067:0.004400:0.009676:0.010024:0.010175:0.004400:0.010205:0.004067:0.004974:0.009752:0.004067:0.004974:0.009071:0.009676:0.004067:0.010160:0.004400:0.002873:0.014030:0.010175:0.004400:0.008104:0.004188
endpoint which was defined as the outcome of the first :@0.519045:0.669644:0.928046:0.669644:0.928046:0.653862:0.519045:0.653862:0.009676:0.009071:0.010205:0.010160:0.009752:0.002873:0.009071:0.004974:0.004959:0.012413:0.009071:0.002873:0.009631:0.009071:0.004959:0.012413:0.010175:0.005715:0.004959:0.010205:0.009676:0.003606:0.003606:0.009071:0.009676:0.010205:0.004959:0.010175:0.005715:0.004959:0.004974:0.009071:0.009676:0.004959:0.009752:0.009041:0.004974:0.009631:0.009752:0.014030:0.009676:0.004959:0.009752:0.004596:0.004959:0.004974:0.009071:0.009676:0.004959:0.003606:0.003606:0.004400:0.005715:0.005125:0.004188
occurrence  of  cardiovascular  death,  non-fatal  myo-:@0.519045:0.684665:0.923797:0.684665:0.923797:0.668882:0.519045:0.668882:0.009752:0.009631:0.009631:0.009041:0.004400:0.004400:0.009676:0.009071:0.009631:0.009676:0.004188:0.005367:0.009752:0.004596:0.004188:0.005367:0.009631:0.010175:0.004400:0.010205:0.002873:0.009752:0.008225:0.010175:0.005715:0.009631:0.009041:0.002873:0.010175:0.004400:0.004188:0.005367:0.010205:0.009676:0.010175:0.004974:0.009071:0.004037:0.004188:0.005367:0.009071:0.009752:0.009071:0.004868:0.004596:0.010175:0.004974:0.010175:0.002873:0.004188:0.005367:0.014030:0.007953:0.009752:0.005020
cardial infarction or non-fatal stroke, with no statistically :@0.519045:0.699686:0.928015:0.699686:0.928015:0.683903:0.519045:0.683903:0.009631:0.010175:0.004400:0.010205:0.002873:0.010175:0.002873:0.005322:0.002873:0.009071:0.004596:0.010175:0.004400:0.009631:0.004974:0.002873:0.009752:0.009071:0.005322:0.009752:0.004400:0.005322:0.009071:0.009752:0.009071:0.004868:0.004596:0.010175:0.004974:0.010175:0.002873:0.005322:0.005715:0.004974:0.004400:0.009752:0.007439:0.009676:0.004037:0.005322:0.012413:0.002873:0.004974:0.009071:0.005322:0.009071:0.009752:0.005322:0.005715:0.004974:0.010175:0.004974:0.002873:0.005715:0.004974:0.002873:0.009631:0.010175:0.002873:0.002873:0.008104:0.004188
significant difference between the two treatments.:@0.519045:0.714706:0.883611:0.714706:0.883611:0.698924:0.519045:0.698924:0.005715:0.002873:0.010024:0.009071:0.002873:0.003606:0.003606:0.009631:0.010175:0.009071:0.004974:0.004037:0.010205:0.002873:0.004596:0.004596:0.009676:0.004400:0.009676:0.009071:0.009631:0.009676:0.004037:0.010160:0.009676:0.004974:0.012413:0.009676:0.009676:0.009071:0.004037:0.004974:0.009071:0.009676:0.004037:0.004974:0.012413:0.009752:0.004037:0.004974:0.004400:0.009676:0.010175:0.004974:0.014030:0.009676:0.009071:0.004974:0.005715:0.004188
6:@0.883414:0.709326:0.888272:0.709326:0.888272:0.700172:0.883414:0.700172:0.004858
 :@0.888273:0.714625:0.892461:0.714625:0.892461:0.698842:0.888273:0.698842:0.004188
DiPePtiDyl PePtiDAse-4 inHibitOrs :@0.519047:0.748387:0.831709:0.748387:0.831709:0.728222:0.519047:0.728222:0.012935:0.005174:0.010348:0.009609:0.010348:0.007761:0.005174:0.012935:0.011457:0.008131:0.005174:0.010348:0.009609:0.010348:0.007761:0.005174:0.012935:0.013674:0.009609:0.009609:0.007761:0.010348:0.005174:0.005174:0.013674:0.012566:0.005174:0.010718:0.005174:0.007761:0.015522:0.010718:0.009609:0.005174
The next class of oral hypoglycaemic agents studied in :@0.519047:0.765180:0.928017:0.765180:0.928017:0.749398:0.519047:0.749398:0.006441:0.009223:0.009827:0.004778:0.009223:0.009827:0.007257:0.005125:0.004778:0.009782:0.003024:0.010326:0.005866:0.005866:0.004793:0.009903:0.004747:0.004778:0.009903:0.004551:0.010326:0.003024:0.004778:0.009223:0.008104:0.010311:0.009903:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.004778:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004778:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.010357:0.004778:0.003024:0.009223:0.004188
RCTs were the dipeptidyl peptidase-4 inhibitors (Dpp-4 :@0.519047:0.780201:0.927972:0.780201:0.927972:0.764418:0.519047:0.764418:0.009177:0.012292:0.006441:0.005866:0.006123:0.012564:0.009827:0.004551:0.009827:0.006123:0.005125:0.009223:0.009827:0.006123:0.010357:0.003024:0.010311:0.009827:0.010311:0.005125:0.003024:0.010357:0.008104:0.003024:0.006138:0.010311:0.009827:0.010311:0.005125:0.003024:0.010357:0.010326:0.005866:0.009827:0.005020:0.008376:0.006138:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.006138:0.005579:0.011249:0.008950:0.008950:0.005020:0.008376:0.004188
inhibitors). Figure 1 shows the mechanism of action of :@0.519047:0.795222:0.928002:0.795222:0.928002:0.779439:0.519047:0.779439:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005579:0.004188:0.006214:0.007333:0.003024:0.010175:0.009192:0.004551:0.009827:0.006153:0.008376:0.006153:0.005866:0.009223:0.009903:0.012564:0.005866:0.006153:0.005125:0.009223:0.009827:0.006199:0.014182:0.009827:0.009782:0.009223:0.010326:0.009223:0.003024:0.005866:0.014182:0.006153:0.009903:0.004747:0.006153:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.006153:0.009903:0.004747:0.004188
 :@0.592087:0.795222:0.596321:0.795222:0.596321:0.778723:0.592087:0.778723:0.004233
 :@0.736837:0.795222:0.741070:0.795222:0.741070:0.778723:0.736837:0.778723:0.004233
this group of drugs. :@0.519032:0.810242:0.662134:0.810242:0.662134:0.794460:0.519032:0.794460:0.005125:0.009223:0.003024:0.005866:0.004188:0.010175:0.004551:0.009903:0.009192:0.010311:0.004188:0.009903:0.004747:0.004188:0.010357:0.004551:0.009192:0.010175:0.005866:0.004188:0.004188
Following ingestion of food,  incretin hormone  GLp-1 :@0.533320:0.825263:0.927987:0.825263:0.927987:0.809480:0.533320:0.809480:0.007333:0.009903:0.003024:0.003024:0.009903:0.012564:0.003024:0.009223:0.010175:0.006683:0.003024:0.009223:0.010175:0.009827:0.005866:0.005125:0.003024:0.009903:0.009223:0.006683:0.009903:0.004747:0.006683:0.004747:0.009903:0.009903:0.010357:0.004188:0.004188:0.002480:0.003024:0.009223:0.009782:0.004551:0.009827:0.005125:0.003024:0.009223:0.006683:0.009223:0.009903:0.004551:0.014182:0.009903:0.009223:0.009827:0.004188:0.002480:0.013184:0.006985:0.008950:0.005020:0.008376:0.004188
is released in the bloodstream which stimulates a glu-:@0.519032:0.840283:0.923784:0.840283:0.923784:0.824501:0.519032:0.824501:0.003024:0.005866:0.006169:0.004551:0.009827:0.003024:0.009827:0.010326:0.005866:0.009827:0.010357:0.006169:0.003024:0.009223:0.006169:0.005125:0.009223:0.009827:0.006169:0.010311:0.003024:0.009903:0.009903:0.010357:0.005866:0.005125:0.004551:0.009827:0.010326:0.014182:0.006169:0.012564:0.009223:0.003024:0.009782:0.009223:0.006169:0.005866:0.005125:0.003024:0.014182:0.009192:0.003024:0.010326:0.005125:0.009827:0.005866:0.006169:0.010326:0.006169:0.010175:0.003024:0.009192:0.005020
cose-dependent release of insulin from the pancreatic :@0.519032:0.855304:0.927972:0.855304:0.927972:0.839521:0.519032:0.839521:0.009782:0.009903:0.005866:0.009827:0.005020:0.010357:0.009827:0.010311:0.009827:0.009223:0.010357:0.009827:0.009223:0.005125:0.004989:0.004551:0.009827:0.003024:0.009827:0.010326:0.005866:0.009827:0.005004:0.009903:0.004747:0.004989:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.005004:0.004747:0.004551:0.009903:0.014182:0.004989:0.005125:0.009223:0.009827:0.004989:0.010311:0.010326:0.009223:0.009782:0.004551:0.009827:0.010326:0.005125:0.003024:0.009782:0.004188
beta cell; it also suppresses glucose-dependent gluca-:@0.519032:0.870325:0.923799:0.870325:0.923799:0.854542:0.519032:0.854542:0.010311:0.009827:0.005125:0.010326:0.005035:0.009782:0.009827:0.003024:0.003024:0.004188:0.005035:0.003024:0.005125:0.005035:0.010326:0.003024:0.005866:0.009903:0.005035:0.005866:0.009192:0.010311:0.010311:0.004551:0.009827:0.005866:0.005866:0.009827:0.005866:0.005035:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.005020:0.010357:0.009827:0.010311:0.009827:0.009223:0.010357:0.009827:0.009223:0.005125:0.005020:0.010175:0.003024:0.009192:0.009782:0.010326:0.005020
gon release from the pancreatic alpha cell. The action :@0.519032:0.885345:0.927987:0.885345:0.927987:0.869563:0.519032:0.869563:0.010175:0.009903:0.009223:0.004551:0.004551:0.009827:0.003024:0.009827:0.010326:0.005866:0.009827:0.004566:0.004747:0.004551:0.009903:0.014182:0.004551:0.005125:0.009223:0.009827:0.004551:0.010311:0.010326:0.009223:0.009782:0.004551:0.009827:0.010326:0.005125:0.003024:0.009782:0.004551:0.010326:0.003024:0.010311:0.009223:0.010326:0.004566:0.009782:0.009827:0.003024:0.003024:0.004188:0.004566:0.006441:0.009223:0.009827:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188
of GLP-1 in the system lasts some three to five minutes :@0.519032:0.900366:0.927987:0.900366:0.927987:0.884583:0.519032:0.884583:0.009903:0.004747:0.005655:0.013184:0.006985:0.008950:0.005020:0.008376:0.005670:0.003024:0.009223:0.005670:0.005125:0.009223:0.009827:0.005670:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.005670:0.003024:0.010326:0.005866:0.005125:0.005866:0.005670:0.005866:0.009903:0.014182:0.009827:0.005655:0.005125:0.009223:0.004551:0.009827:0.009827:0.005655:0.005125:0.009903:0.005655:0.003681:0.003681:0.008376:0.009827:0.005670:0.014182:0.003024:0.009223:0.009192:0.005125:0.009827:0.005866:0.004188
before it is inactivated  by the Dpp-4 enzyme. Thus, :@0.519032:0.915387:0.927987:0.915387:0.927987:0.899604:0.519032:0.899604:0.010311:0.009827:0.004747:0.009903:0.004551:0.009827:0.009026:0.003024:0.005125:0.009026:0.003024:0.005866:0.009026:0.003024:0.009223:0.010326:0.009782:0.005125:0.003024:0.008376:0.010326:0.005125:0.009827:0.010357:0.004188:0.004853:0.010311:0.008104:0.009026:0.005125:0.009223:0.009827:0.009026:0.011249:0.008950:0.008950:0.005020:0.008376:0.009026:0.009827:0.009223:0.006426:0.008104:0.014182:0.009827:0.004188:0.009026:0.006441:0.009223:0.009192:0.005866:0.004188:0.004188
Dpp-4 inhibitors allow for an increase in systemic GLp-1 :@0.519032:0.930407:0.927957:0.930407:0.927957:0.914625:0.519032:0.914625:0.011249:0.008950:0.008950:0.005020:0.008376:0.005292:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005292:0.010326:0.003024:0.003024:0.009903:0.012564:0.005307:0.004747:0.009903:0.004551:0.005292:0.010326:0.009223:0.005292:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.005292:0.003024:0.009223:0.005292:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.005307:0.013184:0.006985:0.008950:0.005020:0.008376:0.004188
levels; the incretin effect.:@0.519032:0.945428:0.701927:0.945428:0.701927:0.929645:0.519032:0.929645:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.004188:0.004188:0.005125:0.009223:0.009827:0.004188:0.003024:0.009223:0.009782:0.004551:0.009827:0.005125:0.003024:0.009223:0.004188:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188
table 1. impact of intensive therapy in diabetes:@0.076180:0.778504:0.422709:0.778504:0.422709:0.762005:0.076180:0.762005:0.006350:0.009979:0.009979:0.003629:0.009676:0.004233:0.008467:0.004233:0.004233:0.004233:0.014212:0.009979:0.009979:0.009676:0.004536:0.004233:0.009676:0.004233:0.004233:0.003629:0.009071:0.004536:0.009676:0.009071:0.006652:0.003629:0.008467:0.009676:0.004233:0.004536:0.009071:0.009676:0.004838:0.009979:0.009979:0.008769:0.004233:0.003629:0.009071:0.004233:0.009979:0.003629:0.009979:0.009979:0.009676:0.004536:0.009676:0.006652
4:@0.422695:0.773135:0.427606:0.773135:0.427606:0.763566:0.422695:0.763566:0.004911